Biotech Values

[DewDiligence]

(MNTA)—NVS probably won’t give investors the generic-Lovenox sales number directly, but investors may be able to ballpark the number by the degree to which NVS ascribes an increase in the guidance for 2010 year-over-year parent-company sales to the contribution from Lovenox.